[Virtual Presenter] We are presenting opportunities for strategic partnership between Bochéry and Dallah Healthcare in Saudi Arabia.. 

Scene 1

[Audio] Our commitment to innovation has led us to develop cutting-edge products that harness the power of nanotechnology and biotechnology. We have been revolutionizing the field since 2007 with our premium skincare brand, Bochéry Lab Esthétique. Our unique approach involves encapsulating our advanced active ingredients within liposomes, allowing for optimal skin penetration and delivering the best possible results. This is our promise to our clients, and it is what drives our vision forward.. 

Scene 2

Bochéry Lab Esthétique  is a premium skincare brand that creates innovative cosmeceutical products, combining the ultimate capacity of nanotechnology and biotechnology, revolutionizing the filed since 2007. 

The liposomal encapsulation of our state-of-the-art active ingredients allows optimal skin penetration, offering best visible results, which is our vision and promise to our clients.

[Audio] Our premium dermal cosmetic products have been carefully crafted to provide exceptional results for our customers. With a focus on quality and innovation, we strive to stay ahead of the curve in the industry. By using only the finest ingredients and cutting-edge technology, we ensure that every product meets the highest standards of excellence. Whether it's enhancing skin tone, reducing fine lines and wrinkles, or providing long-lasting hydration, our products are designed to deliver real results.. 

Scene 3

Boghéry
PREMIUM
DERMAL
COSMETIC
PRODUCTS
Dermal Cosmetics

[Audio] Our dermal fillers offer a range of treatments designed to enhance beauty and restore vitality. With our expertise, we can help you re-treat and renew your skin, addressing concerns such as fine lines, wrinkles, and loss of facial volume. Our dermal fillers are carefully selected to provide optimal results, ensuring a natural-looking appearance that complements your unique features. Whether you're looking to revitalize your complexion or address specific areas of concern, our team is dedicated to helping you achieve your aesthetic goals. 

Scene 4

B chér
3 ESTHETIQUE
Enhance Beauty. Re"ta.lue.
Re Renew W"th
•01.ßA DE kMAL
Dermal Fillers

[Audio] In our fast-paced world, it can be challenging to maintain a balanced diet and get all the essential nutrients our body needs. This is where multivitamins come in. They are a convenient and effective way to supplement our diet and ensure we are getting all the necessary vitamins and minerals. At IEEE Bochéry LAB ESTHÉTIQUE, we understand the importance of incorporating multivitamins into our daily routine. Our experts have carefully formulated a special blend of multivitamins that are specifically designed to nourish and enhance the beauty of your skin. These multivitamins contain powerful antioxidants and essential vitamins that work together to protect your skin from environmental damage and keep it looking youthful and radiant. But it's not just about external beauty. Multivitamins also play a crucial role in our overall health and well-being. They boost our immune system, support healthy brain function, and help prevent chronic diseases. In fact, studies have shown that individuals who take multivitamins regularly are less likely to experience deficiencies and have a lower risk of certain health conditions. So don't underestimate the power of multivitamins. Take the first step towards a healthier and more beautiful you by incorporating our specially formulated multivitamins into your daily routine. With IEEE Bochéry LAB ESTHÉTIQUE, you can achieve optimal skin health and overall wellness.. 

Scene 5

IEEE
Bochéry
LAB ESTHÉTIOUE
Multivitamins

[Audio] LYSASPIR@ is a pharmaceutical product containing LYSINE ACETYLSALICYLATE, an injectable medication used for its analgesic and anti-inflammatory properties. This medication provides relief from pain while being safe for use. The product comes in vial form, with six vials and ampules of solvent included. The manufacturer's name is Bechéyy, and the product has been assigned the registration number 5120765.. 

Scene 6

LYSASPIR@
LYSINE ACETYLSALICYLATE
INJECTABLE I.V./I.M.
Fierce against pain, harmless with you
INJECTABLE BY I.V. I.M.
LYSASPIR @
LYSINE ACETYLSALICYLATE
Analgesic,
Anti-inflammatory
6 Vials • 6 Ampules solvent
Bechéyy
str , athem. no 5120765 .

[Audio] The proposed financial proposal for the strategic partnership between Bochéry and Dallah Healthcare in Saudi Arabia includes a partnership structure where Bochéry will hold a 40% to 50% share, while Dallah Healthcare will hold the remaining share. The duration of the partnership is initially set for three years, with predefined business goals. After the initial term, there are two exit strategy options available: public listing through an initial public offering or a buyout option where Dallah Healthcare can acquire Bochéry's share. The calculation determines the target number of patients to be served by the partnership. The conclusion emphasizes the mutual benefits of the partnership and outlines the next steps for launching in KSA, including approval of partnership terms, regulatory filings, market-specific product trials, deployment of joint marketing campaigns, and setup of distribution channels through Dallah's healthcare network.. 

Scene 7

We currently have presence in Saudi Arabia, registered in Saudi FDA, Qatar, UAE, Kuwait, UK, Canada, Lebanon, Egypt, Iraq and of course in Europe.

[image]. No photo description available.. London. 

Scene 8

[Audio] Bochéry and Dallah Healthcare are entering into a strategic partnership, and it is crucial to recognize the significance of each entity involved. The logos or brand marks displayed represent the distinct identities, values, and missions of each party. By acknowledging these differences, we can better comprehend the unique strengths and contributions they bring to our collaborative efforts. This understanding will enable us to work more efficiently together, combining the expertise and resources of each partner to achieve our shared objectives.. 

Scene 9

[Audio] Assuming we capture 0.5% of the skincare market in key regions, our estimated annual sales would be substantial. The Middle East would generate between $15 million and $20 million annually, driven by the region's large and growing population. In Europe, we anticipate generating around $8 million to $10 million annually, while in Canada and the UK, we expect to reach $5 million to $7 million annually. Overall, our total estimated annual sales would range from $28 million to $37 million.. 

Scene 10

Assuming Bochéry captures 0.5% of the skincare market in key regions:
 Middle East (KSA, UAE, Qatar, Kuwait, Egypt, Iraq, Lebanon): $15M - $20M annually. Europe: $8M - $10M annually. Canada, UK: $5M - $7M annually. Total Estimated Annual Sales: $28M - $37M.

CARING FOOT SAVING LIFE. Innovation way to keep diabetic foot on the way Unique treatment for the diabetic foot ulcers systemically and topically in the world.. 

Scene 11

Innovation way to keep diabetic foot on the way  Unique treatment for  the diabetic foot ulcers systemically and topically in the world.

[Audio] At Bochéry LAB ESTHÉTIQUE, we recognize the difficulties faced by diabetic patients suffering from foot ulcers. Our response has been to develop an advanced, patented treatment product specifically designed to accelerate healing and mitigate potential complications, both locally and systemically.. 

Scene 12

So, At Bochéry LAB ESTHÉTIQUE understand the challenges faced by diabetic patients with foot ulcers. That's why we've developed an advanced  unique, innovative Diabetic Foot Ulcer  patent treatment product designed to promote healing and prevent complications.
 (Not only topically but also systemically as well).

3 Manitaki Str., 10443 Athens, Greece Tel: +30 210 5120765 Fax: +30 210 5150444, info@bochery.com www.bochery.com

[Audio] LYTONIC ™ is the most effective medication for treating the condition, as research indicates. The healing process is enhanced by improving blood circulation in the ulcer, with no side effects reported. This innovative nano-biotechnological product comes in two pharmaceutical forms: gel and capsules, which allow it to work both topically and systemically.. 

Scene 13

Research results indicate that  is the most effective medication for the condition and  enhances the healing process by improving the blood circulation in the ulcer and has no side effects.  LYTONIC ™ available in two pharmaceutical forms (Gel & Capsules) to work topically and systemically. 
 LYTONIC ™

LYTONIC™ is an innovative, unique and patent 
nano-biotechnological product.

[Audio] LYTONIC Plus™ capsules are a powerful oral supplement designed to support lymphatic and blood microcirculation, cells oxygenation, promote antioxidant action, and enhance the body's natural healing processes. These benefits are vital to treat various types of skin ulcers, including diabetic foot ulcers, postoperative ulcers, burns, and bedsores.. 

Scene 14

LYTONIC Plus™ capsules are a powerful oral supplement designed to support lymphatic and blood microcirculation, cells oxygenation, promote antioxidant action, and enhance the body's natural healing processes. 

These benefits are vital to treat the diabetic foot ulcer (DFU), postoperative ulcer, burns, bedsores and any skin ulcers.

[Audio] LYTONIC Gel ™ works through its antioxidant properties, improving blood circulation and strengthening the lymphatic system. This mechanism allows for the removal of dead tissue in the affected area. Additionally, it hydrates and revitalizes damaged skin cells, reduces inflammation, and promotes granulation and reepithelization at the wound site. Furthermore, it enhances lymphatic, blood flow, and oxygenation of damaged tissues, providing a soothing effect and anti-inflammatory action.. 

Scene 15

Mode of action: it`s working through its antioxidant properties, improving blood circulation and strengthening the lymphatic system, it causes the removal of dead tissue in the affected area.

Å.iöipöq
•6uqeuøMxo SuOO
6uqejgY,i." doaa
OINOLO

• Hydrates and revitalizes damaged skin cells. • Reduces inflammation and promotes  the granulation and reepithelization at the wound site. • Enhances lymphatic, blood flow and oxygenation of damaged tissues.
 • Provides a soothing effect and 
anti-inflammatory action .

[Audio] Our treatment approach addresses both systemic and localized factors of Diabetic Foot Ulcer, providing comprehensive care through internal and external applications. This integrated therapy combines the benefits of capsules, which improve lymphatic and blood microcirculation, reducing internal inflammation, with the soothing, hydrating, and protective properties of our gel. By working together, these components accelerate healing, minimize the risk of infection, and promote overall foot health. The synergistic effects of this combined treatment enable effective and efficient recovery from Diabetic Foot Ulcer.. 

Scene 16

-Enhanced Efficacy: The internal and external application provides complete care, addressing both systemic and localized factors of DFU.  -Integrated Therapy: Capsules improve  lymphatic and blood microcirculation  and reduce internal inflammation, while the gel soothes, hydrates, and protects the skin.  -Rapid Recovery: Together, they accelerate healing, reduce infection risk, and support overall foot health.

Certainly, there’s synergistic effects of capsules and Gel working together to treat Diabetic Foot Ulcer: Synergistic Effects

[image] ooocts LYTONIC LYTONIC • PLUS/ CGM system Gluco-Sensor 24h Gluco Sensor 24h from Bochéry V.OIIJ BOCPQÜ Clnco 260201. sqp Bochéry Bbd,péi.ix. 

Scene 17

[image] ooocts
LYTONIC
LYTONIC • PLUS/
CGM system
Gluco-Sensor 24h
Gluco Sensor 24h
from Bochéry
V.OIIJ BOCPQÜ
Clnco 260201. sqp
Bochéry
Bbd,péi.ix

[Audio] Bochéry and Dallah Healthcare are partnering to introduce three products, namely LYTONIC Plus & Gel, Wound Care Plaster, and Gluco-Sensor 24h, to the KSA market. The partnership aims to capitalize on the growing demand for healthcare solutions in the region by combining Bochéry's advanced technology with Dallah Healthcare's expertise. This collaboration is expected to yield mutually beneficial results, providing top-notch healthcare services to the people of KSA.. 

Scene 18

Strategic Partnership Opportunity Bochéry & Dallah Healthcare

LYTONIC Plus & Gel, Wound Care Plaster, and Gluco-Sensor 24h in the KSA Market

[Audio] We envision a future where our strategic partnership with Dallah Healthcare enables us to bring cutting-edge diabetic care solutions to the Kingdom of Saudi Arabia. By combining our expertise and resources, we aim to provide innovative treatments and products that meet the unique needs of the KSA market. This collaboration will not only benefit patients but also drive growth and development in the pharmaceutical industry within the region. Additionally, we are committed to contributing a pharmaceutical production facility in KSA, further solidifying our commitment to this strategic partnership. 

Scene 19

Our  goal of establishing a strategic partnership with Dallah Healthcare to deliver innovative diabetic care solutions to the KSA market, utilizing Dallah's local expertise and Bochéry's advanced healthcare products.
Strategic Cooperation on the sector of Pharmaceutical Industry, we would like to mention that we are in a position to contribute pharmaceutical production facility at KSA.

[Audio] The population of Saudi Arabia has been consistently growing over the years, reaching approximately 34 million people as of 2024. This growth can be attributed to various factors, including advancements in healthcare, a younger demographic structure, and the influx of foreign workers drawn by the country's expanding economic opportunities under Saudi Vision 2030. 

Scene 20

As of 2024, the population of Saudi Arabia is approximately 34 million people. This figure reflects consistent growth influenced by factors such as improved healthcare, a younger demographic structure, and the influx of expatriate workers due to expanding economic opportunities under Saudi Vision 2030​
 General Authority for Statistics Saudi Arabia Today Saudi Press Agency

[Audio] Diabetes affects more than 18 percent of the Saudi Arabian population, which amounts to approximately seven million individuals. The estimated prevalence of diabetic foot ulcers ranges from 15 to 25 percent of these patients, corresponding to a minimum of nearly one million cases and a maximum of almost one and a half million cases. These statistics emphasize the necessity for effective prevention and treatment strategies to reduce the impact of diabetes on those affected.. 

Scene 21

Diabetes and Diabetic Foot Statistics in Saudi Arabia

- Population in Saudi Arabia: Approximately 34 million - Diabetes prevalence: Over 18% of the population - Number of diabetic patients: Approximately 7,000,000
 - Diabetic foot prevalence among diabetic patients: 15% to 25%   * Minimum number of diabetic foot patients (15%): 918,000   * Maximum number of diabetic foot patients (25%): 1,530,000

[Audio] Diabetic Foot Ulcers (DFU) and Amputation in Saudi Arabia are analyzed in terms of risks, amputation rates, and future prevalence from 2024 to 2029. The complications of diabetes, including DFU, can lead to amputation if not properly managed. In Saudi Arabia, the prevalence of DFU and amputation is increasing, affecting the healthcare system and quality of life for patients. Factors contributing to DFU include age, gender, type of diabetes, and access to healthcare. Amputation rates in Saudi Arabia are concerning, with many diabetic patients facing the risk of losing a limb, impacting their physical and mental well-being. The prevalence of DFU and amputation is expected to rise in the coming years, emphasizing the need for effective prevention and management strategies.. 

Scene 22

Diabetic Foot Ulcers (DFU) and Amputation in Saudi Arabia

Analysis of Risks, Amputation Rates, and Future Prevalence (2024-2029)

[Audio] Diabetic Foot Ulcers pose significant risks to patients with diabetes. The main risk factors include neuropathy, which causes loss of sensation in the feet, making it difficult for patients to detect injuries or discomfort. Poor glycemic control also increases the risk of developing DFUs, as does peripheral arterial disease, which reduces blood flow to the extremities. Furthermore, a history of previous foot ulcers significantly raises the likelihood of future occurrences. These risk factors have a profound impact on mortality rates, with patients suffering from DFUs experiencing a mortality rate nearly twice that of those without DFUs. Moreover, amputations, often a consequence of DFUs, lead to even higher mortality rates, reaching as high as 32.2%.. 

Scene 23

• Main Risk Factors:   - Neuropathy (loss of sensation in the feet).   - Poor glycemic control.   - Peripheral arterial disease.   - History of previous foot ulcers. • Impact on Mortality:   - Mortality rate for patients with DFUs: 18.5%, almost twice that of patients without DFUs.   - Amputations lead to even higher mortality rates (32.2%).

[Audio] In Saudi Arabia, it's estimated that between 5% to 15% of diabetic patients with diabetic foot ulcers may require amputations. This translates to over 3000 diabetic-related amputations occurring annually. Furthermore, our data shows that amputation and mortality rates are significantly higher among males, ranging from 76% to 78%.. 

Scene 24

• Annual Amputation Rates:   - 5-15% of diabetic patients with DFUs may require amputations.   - Over 3,000 diabetic-related amputations occur annually. • Gender Impact:   - Amputation and mortality rates are significantly higher among males (76-78%).

[Audio] According to our estimates, by 2024, approximately 7.0 million individuals in Saudi Arabia will have diabetes. This number is expected to rise proportionally, reflecting the growing trend of diabetic foot ulcers, or DFUs. Looking ahead to 2029, we forecast that the prevalence of diabetes will reach 8 million, accompanied by an estimated 20% increase in amputations due to population growth and aging. These statistics underscore the importance of proactive measures to address this critical public health issue.. 

Scene 25

Prevalence and Forecast for the Next 5 Years

• 2024 Estimate:   - Approximately 7.0 million individuals with diabetes in Saudi Arabia.   - DFU rates are rising proportionally. • 2029 Forecast:   - Diabetes prevalence projected to rise to 8 million.   - Estimated increase in amputations by 20% due to population growth and aging.

[Audio] Risks associated with diabetic foot include ulcers and wounds, bacterial infections, amputation, psychological and social impact, and high healthcare costs. These risks can have severe consequences if left untreated or poorly managed.. 

Scene 26

1. Ulcers and Wounds   2. Bacterial Infections     3. Amputation    4. Psychological and Social Impact
 5. High Healthcare Costs

[Audio] The estimated healthcare costs for diabetic foot in Saudi Arabia are substantial. The annual treatment cost per patient ranges between seventy thousand Saudi riyals and one hundred twenty thousand Saudi riyals. This translates to a total annual cost for all patients of approximately seventy-five billion Saudi riyals, assuming an average of one million five hundred thousand patients.. 

Scene 27

Estimated Healthcare Costs for Diabetic Foot in Saudi Arabia

Annual Treatment Cost per Patient: Ranges between SAR 70,000 and SAR 120,000.

* Total Annual Cost for All Patients:
 1- For average 1,500,000 patients: Approximately
 SAR 75 billion.

[Audio] We propose a strategic partnership between Bochéry and Dallah Healthcare in Saudi Arabia. The financial proposal outlines the terms of the partnership, including the structure, duration, and exit strategy options. According to the calculation, our target is to serve patients with diabetic foot ulcers (DFU). We plan to achieve this by establishing a joint venture with a 40% to 50% share held by Bochéry and the remaining share held by Dallah Healthcare. The initial term of the partnership will be three years, during which we will work towards predefined business goals. After the initial term, there are two exit strategy options available: public listing through an initial public offering (IPO), where the company sells shares of its stock to the public on a stock exchange; or a buyout option, where Dallah Healthcare acquires Bochéry's share.. 

Scene 28

Specialized Medical Teams Medical Equipment Extended Hospital Stays Chronic Complications

[Audio] Prevention is crucial in managing diabetic foot ulcers. Educating the public and at-risk individuals through health awareness programs can prevent the onset of these complications. Additionally, ensuring better management and monitoring of diabetic patients through improved foot care can significantly reduce the risk of developing mild cases. This proactive approach will ultimately prevent the escalation of the disease, reducing the need for costly treatments and hospitalizations.. 

Scene 29

Health Awareness Programs
 Improved Foot Care for Diabetic Patients
 Early Detection and Management of Mild Cases

[Audio] In Saudi Arabia, there are approximately 500 government and private hospitals providing treatment and care for diabetic foot patients. More than 50 specialized centers focus on treating and managing diabetes and diabetic foot, managed by the Ministry of Health or the private sector. Many hospitals also have specialized units or departments for diabetic foot care, particularly in major hospitals like National Guard hospitals, King Faisal Specialist Hospital, Dallah Hospital, and Dr. Sulaiman Al Habib Hospital. Hundreds of outpatient clinics offer diabetic foot care services, including primary healthcare centers under the Ministry of Health. Notable facilities in this field include King Faisal Specialist Hospital & Research Center, National Guard Health Affairs Hospitals, Dallah Hospital Group, Dr. Sulaiman Al Habib Hospitals, and Diabetes Centers affiliated with the Ministry of Health across various regions.. 

Scene 30

Number of Medical Centers and Hospitals in Saudi Arabia Providing Diabetic Foot Care

[Audio] The pharmaceutical market in Saudi Arabia has seen significant growth in recent years, and it is estimated to be over USD 6 billion. Oral medications are the most commonly prescribed treatment for diabetes in Saudi Arabia, but there is an increasing demand for insulin and other injectable treatments. Understanding market trends and consumer preferences is crucial for effective marketing and developing tailored strategies that can improve diabetes care in Saudi Arabia.. 

Scene 31

Analysis of the Current Market Value and Diabetes-related Treatments

[Audio] The current market value of pharmaceuticals in Saudi Arabia was SAR 44 billion, which is equivalent to USD 12 billion, in 2022. This figure is expected to rise to SAR 57 billion, or USD 15 billion, by 2027, representing a CAGR of 5.2%.. 

Scene 32

The current market value of pharmaceuticals in Saudi Arabia: - SAR 44 billion (USD 12 billion) in 2022
 - Expected to reach SAR 57 billion (USD 15 billion) by 2027 - CAGR “Compounded Annual Growth Rate “: 5.2%

[Audio] We will partner with reputable pharmaceutical companies such as Jamjoom Pharma, Avalon Pharma, Tabuk Pharmaceuticals, and SPIMACO to provide high-quality treatment options for our patients. Our focus will be on topical treatments only, ensuring the most effective and efficient care for those we serve.. 

Scene 33

Companies and DFU Treatment “Topical Only”

Companies: - Jamjoom Pharma - Avalon Pharma - Tabuk Pharmaceuticals - SPIMACO (Saudi Pharmaceutical Industries)

[Audio] The key players in the KSA market are notable competitors across various categories. Johnson & Johnson, Smith & Nephew, and Mölnlycke Health Care offer patch solutions in the area of Diabetic Foot Ulcer care. Abbott's Freestyle Libre, Medtronic's Guardian, and Dexcom provide Continuous Glucose Monitoring Systems. 3M Healthcare, Smith & Nephew, and regional distributors supply wound care plasters. These competitors shape the market landscape.. 

Scene 34

Notable competitors across categories include:
 - DFU  (Diabetic Foot Ulcer) Care / only patches: 
Johnson & Johnson, Smith & Nephew, Mölnlycke Health Care
 - CGMS Continuous Glucose Monitoring System : 
Abbott (Freestyle Libre), Medtronic (Guardian), Dexcom
 - Wound Care Plasters: 
3M Healthcare, Smith & Nephew, regional distributors

[Audio] Each product line requires a significant upfront investment, including regulatory approvals and marketing efforts. This investment is crucial for establishing a strong foundation for our partnership. We estimate that this initial investment will amount to two million dollars. With this investment, we can ensure that our products meet the necessary standards and regulations, and that we have a solid plan in place for promoting them to the market.. 

Scene 35

A strategic investment is required for each product line, including regulatory approvals and marketing.
- Initial Investment : $2 Million

[Audio] The partnership between Bochéry and Dallah Healthcare offers numerous benefits for both parties by combining our expertise and resources to bring innovative products and services to the Saudi Arabian market, improving the lives of patients and enhancing the reputation of our companies. To launch our partnership in KSA, we need to approve the partnership terms, ensuring that all parties understand their roles and responsibilities, which involves regulatory filings and market-specific product trials to ensure compliance with local laws and regulations. Next, we will deploy joint marketing campaigns to raise awareness about our partnership and promote our products and services, setting up distribution channels through Dallah's extensive healthcare network, making it easier for patients to access our offerings. By working together, we can achieve great things and create a lasting impact in the healthcare industry.. 

Scene 36

Emphasize the partnership's mutual benefits and outline the next steps for launching in KSA. Approval of partnership terms. Regulatory filings and market-specific product trials. Deployment of joint marketing campaigns. Setup distribution channels through Dallah’s healthcare network.

[image] Gluco Sensor 24b Bochéry
from Bochéry
B•xpfO
S•tp

[Audio] The calculation process for determining our target to serve DFU patients involves defining the target audience, gathering relevant data and information, analyzing the information to identify patterns and trends, setting a realistic and achievable target based on the analysis, and continuously reviewing and adjusting the target as needed.. 

Scene 37

Determine of our target to serve DFU patient

[image] ifnr DFW] Prn-Rt *Min
LYTONIC Plus 30 cap.
LYTONIC Gel 40mI
Wound Care products
Dosage
Dosage
Dosage
Number of Consumed
Packs/ one month
Number of Consumed
Cost Forecast / one DFIJ Patient BY SAR
Target 1 % from total DFIJ Patient (1,530,000 Patients)
Cost Forecast / Target DFIJ Patient BY SAR
At least Estimated Profit Margin 25%
SAR
SAR
15,300
Packs/ Year
86,400
330 480 ooo
82 620 ooo

[Audio] Bochéry and Dallah Healthcare propose a financial plan for their strategic partnership in Saudi Arabia. The plan involves an initial investment of $2 million for establishing a state-of-the-art facility, hiring and training staff, and marketing services. The projected revenue shows a steady increase in demand for aesthetic services, driven by growing awareness and interest among the population. The proposal outlines costs and profits for each year, considering potential operational challenges and market fluctuations. The partnership aims to achieve a significant return on investment within the first three years and contribute to the growth and development of the aesthetic industry in Saudi Arabia.. 

Scene 38

Financial Proposal for Strategic Partnership

Bochéry and Dallah Healthcare - Saudi Arabia

[Audio] The proposed terms outline the structure and duration of our partnership. Bochéry will retain a significant stake in the venture, holding between 40% to 50% of the shares. The remaining shares will be held by Dallah Healthcare. This partnership structure ensures both parties have a vested interest in the success of our joint endeavor. The duration of this partnership has been set at three years, during which we will work together to achieve specific business objectives. Upon completion of the initial term, we have outlined two exit strategy options. We can explore a public listing through an initial public offering, allowing us to sell shares of our stock to the public on a stock exchange. Alternatively, Dallah Healthcare may choose to acquire Bochéry's share, solidifying their position within the partnership.. 

Scene 39

1. Partnership Structure: - Bochéry will hold a 40% to 50% share. - Dallah Healthcare will hold the remaining share.
 2. Duration: - Initial term of 3 years, with predefined business goals.
 3. Exit Strategy Options Post-3 Years: - Public Listing (IPO) initial public offering, company sells shares of its stock to the public on a stock exchange. 
 - Buyout Option: Dallah may acquire Bochéry's share.

[Audio] The references used in this report come from reputable sources. The Saudi Health Council's annual diabetes reports from 2024 provide valuable information on the current state of diabetes in Saudi Arabia. The World Health Organization's global diabetes data from 2023 gives us insight into the global picture of diabetes. The International Journal of Diabetes Research, published in 2024, is dedicated to publishing research on diabetes and its related topics. These sources have been carefully selected to ensure the accuracy and reliability of the information presented in this report.. 

Scene 40

• Source 1: Saudi Health Council, Annual Diabetes Reports (2024). • Source 2: WHO Global Diabetes Data (2023). • Source 3: International Journal of Diabetes Research (2024).

[Audio] The presentation has concluded, and I would like to express my sincere gratitude to everyone who attended for their attention. Our exploration of the significance of shifting the focus on diabetic foot ulcer treatment and wound care in Saudi Arabia has highlighted the potential for a substantial impact on the region's healthcare future. Once more, thank you for your consideration, and I wish you all the best in your efforts to enhance the lives of those affected by diabetes.. 

Scene 41

Bochéry & Dallah Healthcare
A Strategic Alliance for Saudi Arabia’s Future in Diabetic Care

Changing the Perspective on Diabetic Foot  Ulcer Treatment And Wound Care

Strategic Partnership Opportunity: Bochéry & Dallah Healthcare

Our commitment to innovation has led us to develop cutting edge products that harness the power of nanotechnology and biotechnology. We have been revolutionizing the field since 2007 with our premium skincare brand, Bochéry Lab Esthétique. Our unique approach involves encapsulating our advanced active ingredients within liposomes, allowing for optimal skin penetration and delivering the best possible results. This is our promise to our clients, and it is what drives our vision forward.

avatar

Our premium dermal cosmetic products have been carefully crafted to provide exceptional results for our customers. With a focus on quality and innovation, we strive to stay ahead of the curve in the industry. By using only the finest ingredients and cutting edge technology, we ensure that every product meets the highest standards of excellence. Whether it's enhancing skin tone, reducing fine lines and wrinkles, or providing long lasting hydration, our products are designed to deliver real results.

Our dermal fillers offer a range of treatments designed to enhance beauty and restore vitality. With our expertise, we can help you re treat and renew your skin, addressing concerns such as fine lines, wrinkles, and loss of facial volume. Our dermal fillers are carefully selected to provide optimal results, ensuring a natural looking appearance that complements your unique features. Whether you're looking to revitalize your complexion or address specific areas of concern, our team is dedicated to helping you achieve your aesthetic goals

In our fast paced world, it can be challenging to maintain a balanced diet and get all the essential nutrients our body needs. This is where multivitamins come in. They are a convenient and effective way to supplement our diet and ensure we are getting all the necessary vitamins and minerals. At I-E-E-E Bochéry LAB ESTHÉTIQUE, we understand the importance of incorporating multivitamins into our daily routine. Our experts have carefully formulated a special blend of multivitamins that are specifically designed to nourish and enhance the beauty of your skin. These multivitamins contain powerful antioxidants and essential vitamins that work together to protect your skin from environmental damage and keep it looking youthful and radiant. But it's not just about external beauty. Multivitamins also play a crucial role in our overall health and well being. They boost our immune system, support healthy brain function, and help prevent chronic diseases. In fact, studies have shown that individuals who take multivitamins regularly are less likely to experience deficiencies and have a lower risk of certain health conditions. So don't underestimate the power of multivitamins. Take the first step towards a healthier and more beautiful you by incorporating our specially formulated multivitamins into your daily routine. With I-E-E-E Bochéry LAB ESTHÉTIQUE, you can achieve optimal skin health and overall wellness.

LYSASPIR@ is a pharmaceutical product containing LYSINE acetylsalicylate, an injectable medication used for its analgesic and anti inflammatory properties. This medication provides relief from pain while being safe for use. The product comes in vial form, with six vials and ampules of solvent included. The manufacturer's name is Bechéyy, and the product has been assigned the registration number 5120765.

The proposed financial proposal for the strategic partnership between Bochéry and Dallah Healthcare in Saudi Arabia includes a partnership structure where Bochéry will hold a 40% to 50% share, while Dallah Healthcare will hold the remaining share. The duration of the partnership is initially set for three years, with predefined business goals. After the initial term, there are two exit strategy options available: public listing through an initial public offering or a buyout option where Dallah Healthcare can acquire Bochéry's share. The calculation determines the target number of patients to be served by the partnership. The conclusion emphasizes the mutual benefits of the partnership and outlines the next steps for launching in K-S-A--, including approval of partnership terms, regulatory filings, market specific product trials, deployment of joint marketing campaigns, and setup of distribution channels through Dallah's healthcare network.

Bochéry and Dallah Healthcare are entering into a strategic partnership, and it is crucial to recognize the significance of each entity involved. The logos or brand marks displayed represent the distinct identities, values, and missions of each party. By acknowledging these differences, we can better comprehend the unique strengths and contributions they bring to our collaborative efforts. This understanding will enable us to work more efficiently together, combining the expertise and resources of each partner to achieve our shared objectives.

Assuming we capture 0.5% of the skincare market in key regions, our estimated annual sales would be substantial. The Middle East would generate between 15  million dollars and 20  million dollars annually, driven by the region's large and growing population. In Europe, we anticipate generating around 8  million dollars to 10  million dollars annually, while in Canada and the UK, we expect to reach 5  million dollars to 7  million dollars annually. Overall, our total estimated annual sales would range from 28  million dollars to 37  million dollars.

At Bochéry LAB ESTHÉTIQUE, we recognize the difficulties faced by diabetic patients suffering from foot ulcers. Our response has been to develop an advanced, patented treatment product specifically designed to accelerate healing and mitigate potential complications, both locally and systemically.

slide12-hotlinkundefined

  3 Manitaki Str., 10443 Athens, Greece Tel: +30 210 5120765 Fax: +30 210 5150444, info@bochery.com www.bochery.com 

slide12-hotlink41

LYTONIC ™ is the most effective medication for treating the condition, as research indicates. The healing process is enhanced by improving blood circulation in the ulcer, with no side effects reported. This innovative nano biotechnological product comes in two pharmaceutical forms: gel and capsules, which allow it to work both topically and systemically.

slide13-hotlinkundefined

slide13-hotlink34

LYTONIC Plus™ capsules are a powerful oral supplement designed to support lymphatic and blood microcirculation, cells oxygenation, promote antioxidant action, and enhance the body's natural healing processes. These benefits are vital to treat various types of skin ulcers, including diabetic foot ulcers, postoperative ulcers, burns, and bedsores.

slide14-hotlinkundefined

slide14-hotlink15

LYTONIC Gel ™ works through its antioxidant properties, improving blood circulation and strengthening the lymphatic system. This mechanism allows for the removal of dead tissue in the affected area. Additionally, it hydrates and revitalizes damaged skin cells, reduces inflammation, and promotes granulation and reepithelization at the wound site. Furthermore, it enhances lymphatic, blood flow, and oxygenation of damaged tissues, providing a soothing effect and anti inflammatory action.

slide15-hotlinkundefined

slide15-hotlink7

Our treatment approach addresses both systemic and localized factors of Diabetic Foot Ulcer, providing comprehensive care through internal and external applications. This integrated therapy combines the benefits of capsules, which improve lymphatic and blood microcirculation, reducing internal inflammation, with the soothing, hydrating, and protective properties of our gel. By working together, these components accelerate healing, minimize the risk of infection, and promote overall foot health. The synergistic effects of this combined treatment enable effective and efficient recovery from Diabetic Foot Ulcer.

slide16-hotlinkundefined

slide16-hotlink48

Bochéry and Dallah Healthcare are partnering to introduce three products, namely LYTONIC Plus & Gel, Wound Care Plaster, and Gluco Sensor 24 hours, to the K-S-A market. The partnership aims to capitalize on the growing demand for healthcare solutions in the region by combining Bochéry's advanced technology with Dallah Healthcare's expertise. This collaboration is expected to yield mutually beneficial results, providing top notch healthcare services to the people of K-S-A-.

We envision a future where our strategic partnership with Dallah Healthcare enables us to bring cutting edge diabetic care solutions to the Kingdom of Saudi Arabia. By combining our expertise and resources, we aim to provide innovative treatments and products that meet the unique needs of the K-S-A market. This collaboration will not only benefit patients but also drive growth and development in the pharmaceutical industry within the region. Additionally, we are committed to contributing a pharmaceutical production facility in K-S-A--, further solidifying our commitment to this strategic partnership

The population of Saudi Arabia has been consistently growing over the years, reaching approximately 34 million people as of 2024. This growth can be attributed to various factors, including advancements in healthcare, a younger demographic structure, and the influx of foreign workers drawn by the country's expanding economic opportunities under Saudi Vision 2030

Diabetes affects more than 18 percent of the Saudi Arabian population, which amounts to approximately seven million individuals. The estimated prevalence of diabetic foot ulcers ranges from 15 to 25 percent of these patients, corresponding to a minimum of nearly one million cases and a maximum of almost one and a half million cases. These statistics emphasize the necessity for effective prevention and treatment strategies to reduce the impact of diabetes on those affected.

Diabetic Foot Ulcers (D-F-U--) and Amputation in Saudi Arabia are analyzed in terms of risks, amputation rates, and future prevalence from 2024 to 2029. The complications of diabetes, including D-F-U--, can lead to amputation if not properly managed. In Saudi Arabia, the prevalence of D-F-U and amputation is increasing, affecting the healthcare system and quality of life for patients. Factors contributing to D-F-U include age, gender, type of diabetes, and access to healthcare. Amputation rates in Saudi Arabia are concerning, with many diabetic patients facing the risk of losing a limb, impacting their physical and mental well being. The prevalence of D-F-U and amputation is expected to rise in the coming years, emphasizing the need for effective prevention and management strategies.

Diabetic Foot Ulcers pose significant risks to patients with diabetes. The main risk factors include neuropathy, which causes loss of sensation in the feet, making it difficult for patients to detect injuries or discomfort. Poor glycemic control also increases the risk of developing D-F-U-s-, as does peripheral arterial disease, which reduces blood flow to the extremities. Furthermore, a history of previous foot ulcers significantly raises the likelihood of future occurrences. These risk factors have a profound impact on mortality rates, with patients suffering from D-F-U's experiencing a mortality rate nearly twice that of those without D-F-U-s-. Moreover, amputations, often a consequence of D-F-U-s-, lead to even higher mortality rates, reaching as high as 32.2%.

In Saudi Arabia, it's estimated that between 5% to 15% of diabetic patients with diabetic foot ulcers may require amputations. This translates to over 3000 diabetic related amputations occurring annually. Furthermore, our data shows that amputation and mortality rates are significantly higher among males, ranging from 76% to 78%.

According to our estimates, by 2024, approximately 7.0 million individuals in Saudi Arabia will have diabetes. This number is expected to rise proportionally, reflecting the growing trend of diabetic foot ulcers, or D-F-U-s-. Looking ahead to 2029, we forecast that the prevalence of diabetes will reach 8 million, accompanied by an estimated 20% increase in amputations due to population growth and aging. These statistics underscore the importance of proactive measures to address this critical public health issue.

Risks associated with diabetic foot include ulcers and wounds, bacterial infections, amputation, psychological and social impact, and high healthcare costs. These risks can have severe consequences if left untreated or poorly managed.

The estimated healthcare costs for diabetic foot in Saudi Arabia are substantial. The annual treatment cost per patient ranges between seventy thousand Saudi riyals and one hundred twenty thousand Saudi riyals. This translates to a total annual cost for all patients of approximately seventy five billion Saudi riyals, assuming an average of one million five hundred thousand patients.

We propose a strategic partnership between Bochéry and Dallah Healthcare in Saudi Arabia. The financial proposal outlines the terms of the partnership, including the structure, duration, and exit strategy options. According to the calculation, our target is to serve patients with diabetic foot ulcers (D-F-U--). We plan to achieve this by establishing a joint venture with a 40% to 50% share held by Bochéry and the remaining share held by Dallah Healthcare. The initial term of the partnership will be three years, during which we will work towards predefined business goals. After the initial term, there are two exit strategy options available: public listing through an initial public offering (I-P-O--), where the company sells shares of its stock to the public on a stock exchange; or a buyout option, where Dallah Healthcare acquires Bochéry's share.

Prevention is crucial in managing diabetic foot ulcers. Educating the public and at risk individuals through health awareness programs can prevent the onset of these complications. Additionally, ensuring better management and monitoring of diabetic patients through improved foot care can significantly reduce the risk of developing mild cases. This proactive approach will ultimately prevent the escalation of the disease, reducing the need for costly treatments and hospitalizations.

In Saudi Arabia, there are approximately 500 government and private hospitals providing treatment and care for diabetic foot patients. More than 50 specialized centers focus on treating and managing diabetes and diabetic foot, managed by the Ministry of Health or the private sector. Many hospitals also have specialized units or departments for diabetic foot care, particularly in major hospitals like National Guard hospitals, King Faisal Specialist Hospital, Dallah Hospital, and Dr  Sulaiman Al Habib Hospital. Hundreds of outpatient clinics offer diabetic foot care services, including primary healthcare centers under the Ministry of Health. Notable facilities in this field include King Faisal Specialist Hospital & Research Center, National Guard Health Affairs Hospitals, Dallah Hospital Group, Dr  Sulaiman Al Habib Hospitals, and Diabetes Centers affiliated with the Ministry of Health across various regions.

The pharmaceutical market in Saudi Arabia has seen significant growth in recent years, and it is estimated to be over USD 6 billion. Oral medications are the most commonly prescribed treatment for diabetes in Saudi Arabia, but there is an increasing demand for insulin and other injectable treatments. Understanding market trends and consumer preferences is crucial for effective marketing and developing tailored strategies that can improve diabetes care in Saudi Arabia.

The current market value of pharmaceuticals in Saudi Arabia was SAR 44 billion, which is equivalent to USD 12 billion, in 2022. This figure is expected to rise to SAR 57 billion, or USD 15 billion, by 2027, representing a C-A-G-R of 5.2%.

We will partner with reputable pharmaceutical companies such as Jamjoom Pharma, Avalon Pharma, Tabuk Pharmaceuticals, and SPIMACO to provide high quality treatment options for our patients. Our focus will be on topical treatments only, ensuring the most effective and efficient care for those we serve.

The key players in the K-S-A market are notable competitors across various categories. Johnson & Johnson, Smith & Nephew, and Mölnlycke Health Care offer patch solutions in the area of Diabetic Foot Ulcer care. Abbott's Freestyle Libre, Medtronic's Guardian, and Dexcom provide Continuous Glucose Monitoring Systems. 3M Healthcare, Smith & Nephew, and regional distributors supply wound care plasters. These competitors shape the market landscape.

Each product line requires a significant upfront investment, including regulatory approvals and marketing efforts. This investment is crucial for establishing a strong foundation for our partnership. We estimate that this initial investment will amount to two million dollars. With this investment, we can ensure that our products meet the necessary standards and regulations, and that we have a solid plan in place for promoting them to the market.

The partnership between Bochéry and Dallah Healthcare offers numerous benefits for both parties by combining our expertise and resources to bring innovative products and services to the Saudi Arabian market, improving the lives of patients and enhancing the reputation of our companies. To launch our partnership in K-S-A--, we need to approve the partnership terms, ensuring that all parties understand their roles and responsibilities, which involves regulatory filings and market specific product trials to ensure compliance with local laws and regulations. Next, we will deploy joint marketing campaigns to raise awareness about our partnership and promote our products and services, setting up distribution channels through Dallah's extensive healthcare network, making it easier for patients to access our offerings. By working together, we can achieve great things and create a lasting impact in the healthcare industry.

The calculation process for determining our target to serve D-F-U patients involves defining the target audience, gathering relevant data and information, analyzing the information to identify patterns and trends, setting a realistic and achievable target based on the analysis, and continuously reviewing and adjusting the target as needed.

Bochéry and Dallah Healthcare propose a financial plan for their strategic partnership in Saudi Arabia. The plan involves an initial investment of 2  million dollars for establishing a state of the art facility, hiring and training staff, and marketing services. The projected revenue shows a steady increase in demand for aesthetic services, driven by growing awareness and interest among the population. The proposal outlines costs and profits for each year, considering potential operational challenges and market fluctuations. The partnership aims to achieve a significant return on investment within the first three years and contribute to the growth and development of the aesthetic industry in Saudi Arabia.

The proposed terms outline the structure and duration of our partnership. Bochéry will retain a significant stake in the venture, holding between 40% to 50% of the shares. The remaining shares will be held by Dallah Healthcare. This partnership structure ensures both parties have a vested interest in the success of our joint endeavor. The duration of this partnership has been set at three years, during which we will work together to achieve specific business objectives. Upon completion of the initial term, we have outlined two exit strategy options. We can explore a public listing through an initial public offering, allowing us to sell shares of our stock to the public on a stock exchange. Alternatively, Dallah Healthcare may choose to acquire Bochéry's share, solidifying their position within the partnership.

The references used in this report come from reputable sources. The Saudi Health Council's annual diabetes reports from 2024 provide valuable information on the current state of diabetes in Saudi Arabia. The World Health Organization's global diabetes data from 2023 gives us insight into the global picture of diabetes. The International Journal of Diabetes Research, published in 2024, is dedicated to publishing research on diabetes and its related topics. These sources have been carefully selected to ensure the accuracy and reliability of the information presented in this report.

The presentation has concluded, and I would like to express my sincere gratitude to everyone who attended for their attention. Our exploration of the significance of shifting the focus on diabetic foot ulcer treatment and wound care in Saudi Arabia has highlighted the potential for a substantial impact on the region's healthcare future. Once more, thank you for your consideration, and I wish you all the best in your efforts to enhance the lives of those affected by diabetes.